Regarding gadolinium-based contrast agents (GBCAs) and nephrogenic systemic fibrosis (NSF), which agent group carries the LOWEST risk due to its macrocyclic and ionic structure?

• A Macrocyclic ionic agents (e.g., gadoterate meglumine, gadoteridol) ✓
• B Linear non-ionic agents (e.g., gadodiamide, gadoversetamide)
• C Linear ionic agents (e.g., gadopentetate dimeglumine — Magnevist)
• D All GBCAs carry equivalent NSF risk regardless of structure

Explanation

NSF risk with GBCAs is directly related to chelate stability (tendency to release free gadolinium). Macrocyclic agents form a more rigid cage structure that tightly binds gadolinium, making transmetallation less likely. Among these, ionic macrocyclic agents (gadoterate meglumine — Dotarem; gadoteridol — ProHance) have the highest kinetic stability and virtually no confirmed NSF cases. Linear non-ionic agents (gadodiamide — Omniscan; gadoversetamide — OptiMARK) have the weakest chelation and the highest NSF risk — they are contraindicated in eGFR <30. Linear ionic agents (gadopentetate — Magnevist) are intermediate risk. Current guidelines (EMA, ACR) classify agents into Group I (high risk — linear non-ionic) and Group II (low risk — macrocyclic).

Reference: Grainger & Allison's Diagnostic Radiology, 7th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.